Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

  • April, 09 2014  | Congratulations to Dr. Elizabeth Jaffee on selection to lead Stand Up To Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team  READ IT HERE
  • April, 08 2014  | Congratulations to Drs. Dung Le and Todd Crocenzi for award of 2014 Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant  READ IT HERE
  • March, 07 2014  | Dirk Brockstedt presents at the 11th Annual International Symposium on Malignant Mesothelioma (first presentation on video, ends at 15:45)  WATCH IT HERE
  • February, 20 2014  | Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer  READ IT HERE
  • February, 19 2014  | Chief Executive Officer, Stephen Isaacs presents at BIO CEO & Investor Conference (registration required to view video)  WATCH IT HERE
  • February, 10 2014  | Aduro BioTech announces initiation of Phase 2b ECLIPSE trial to evaluate treatment of patients with pancreatic cancer with the company’s innovative immunotherapies  READ IT HERE
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use